James Lu

Selected transactions include the following representations:

• 3E Bioventures as the lead investor in Neural Galaxy’s US$75 million Series A financing*
• ADARx Pharmaceuticals in four rounds of equity financing with approximately US$347 million in proceeds
• Ablaze Pharmaceuticals in its US$75 million Series A financing*
• Akeso Biopharma’s US$5 billion collaboration and licensing agreement with Summit Therapeutics to out-license its bispecific antibody, ivonescimab
• Akeso Biopharma in four rounds of equity financing with approximately US$220 million in proceeds*
• Akeso Biopharma’s out-licensing of its CTLA-4 monoclonal antibody to Merck & Co., Inc.*
• Akeso Biopharma’s formation of a joint venture with Chia Tai Tianqing Pharma (CTTQ), a subsidiary of Sino Biopharma*
• EpimAb Biotherapeutics in three rounds of equity financing with approximately US$220 million in proceeds*
• EpimAb Biotherapeutics’ multi-target bio-specific antibody collaboration with Innovent Biologics*
• Chengwei Capital’s equity investments in Hutoon, Bolome, Blueware and Leyaoyao*
• Crown Bioscience in its acquisition of the IndivuServ business unit of Indivumed GmbH
• Crown Bioscience’s acquisition of Molecular Response’s PDX business*
• Crown Bioscience’s acquisition of Preclinomics, Inc.*
• Crown Bioscience’s spinoff of its therapeutics business*
• Crown Bioscience’s sale to JSR Corporation for US$400 million*
• Decheng Capital’s equity investments in AccuGen, Cirina, Everest Medicines, Hummingbird Bioscience, Impact Therapeutics, and Take2*
• Grab Holdings Inc. in six rounds of equity financing with approximately US$1.5 billion in aggregate proceeds*
• HOPU Investments and Yuanmin Capital’s US$200 million equity investment in Mevion Medical Systems*
• Keymed Biosciences’ US$1.1 billion license agreement with AstraZeneca to out-license its Claudin 18.2 antibody drug conjugate
• Morgan Stanley, UBS, Evercore, and others in Grab Holdings Inc.’s SPAC merger*
• Lucid Hearing’s product sales and service agreement with an international retailer*
• Luqa Ventures’ sale to China Medical Systems*
• ProfoundBio in three rounds of equity financing with approximately US$138 million in aggregate proceeds*
• Qiming Venture Partners’ equity investments in Belief Biomed, FraudMetrix and imToken
• ReCode Therapeutics in its US$50 million extension to its Series B financing, for a total of US$260 million in Series B funding
• Runda Medical’s acquisition of Hycor Biomedical*
• Simcere Pharmaceutical Group’s in-licensing of rights to paxalisib from Kazia Therapeutics*
• Simcere Pharmaceutical Group’s strategic partnership with Avilex Pharma to develop and commercialize AVLX144*
• Simcere Pharmaceutical Group’s collaboration and license agreement with Aeromics, Inc. for AER-271*
• Telstra Ventures’ equity investments in Algoblu, Cloopen, Fintell, Gorilla, Hypereal, Qiniu, UBtech, and Xtransfer*
• Temasek Holdings’ equity investments in Mobike and LinkDoc*

 *Matters handled prior to joining Sidley.